3034 results for "Psilocybin"
Horizontal gene cluster transfer increased hallucinogenic mushroom diversity
Evolution Letters – February 27, 2018
Summary
The potent hallucinogen psilocybin is produced by diverse Agaricales mushrooms via horizontal gene transfer. Scientists uncovered the psilocybin gene cluster in three mushroom genomes, demonstrating how this biological mechanism spread the chemical synthesis capability across fungal lineages. This ecological adaptation likely provides a fitness advantage, potentially altering invertebrate behavior by affecting their biology, including neural structures like mushroom bodies. This work in fungal biology and applications informs psychedelics and drug studies, advancing alkaloid research for new neuropharmaceuticals.
Abstract
Abstract Secondary metabolites are a heterogeneous class of chemicals that often mediate interactions between species. The tryptophan-derived secon...
5-Year Trends in Use of Hallucinogens and Other Adjunct Drugs among UK Dance Drug Users
European Addiction Research – December 18, 2006
Summary
A significant shift in drug use patterns emerged among people in dance contexts. While LSD use declined, a sharp rise in psilocybin, a potent hallucinogen, was observed between 2002–2003. Ketamine and other adjunct drugs also showed increasing prevalence from 1999–2003. These trends, vital for Psychedelics and Drug Studies and Forensic Toxicology and Drug Analysis, highlight evolving drug choices. Understanding their Neurotransmitter Receptor Influence on Behavior is crucial for psychological intervention and psychiatry, as some hallucinogens like psilocybin are explored as potential medicine.
Abstract
<i>Aims:</i> To describe and assess trends in the use of hallucinogens and other adjunct drugs over a 5-year period. <i>Design:&l...
Analysis of Aeruginascin in Fruit Bodies of the Mushroom Inocybe aeruginascens
International Journal of Crude Drug Research – January 01, 1989
Summary
A unique compound, aeruginascin, appears to consistently induce euphoria during the ingestion of certain mushrooms. An investigation into ten fruit bodies of *Inocybe aeruginascens*, an Agaricales species, revealed aeruginascin present in similar concentrations to the potent hallucinogen psilocybin. This finding in Fungal Biology suggests aeruginascin modifies psilocybin's pharmacological action. Psychedelics and Drug Studies could explore the Chemistry of these alkaloids, potentially informing chemical synthesis for therapeutic applications, ensuring predictable, positive experiences.
Abstract
Analysis of ten fruit bodies of Inocybe aeruginascens Babos revealed a content of the indole derivative aeruginascin which was in the same order of...
Abuse of the mushroom Panaeolus foenisecii.
BMJ – February 16, 1980
Summary
The *Panaeolus foenesecii* mushroom presents a fascinating complexity for Plant-based Medicinal Research: psilocybin and psilocin, compounds with potential for Medicine and even Cancer Treatment, are inconsistently present. While approximately 60% of analyzed specimens contain these substances, others do not, leading to its classification as a "latent psilocybin" mushroom. This variability complicates precise pharmacological understanding and raises concerns about Mushroom poisoning. Leveraging Data science and Computer science to analyze chemical profiles, perhaps by collating global reports from the World Wide Web, is crucial for advancing our knowledge in this area.
Abstract
CommentReports on the presence of psilocybin and psilocin in Panaeolus foenesecii are confused, since both have been detected in some samples of th...
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
Life – July 29, 2021
Summary
Psilocybin, a potent hallucinogen, demonstrates remarkable promise for treating depressive symptoms. A review of 14 clinical trials from the last 10 years in Psychedelics and Drug Studies found this serotonergic compound, derived from chemical synthesis and alkaloids, significantly reduced depression. One study even showed psilocybin's efficacy comparable to escitalopram, a standard medicine. No serious adverse effect was reported. This Neurotransmitter Receptor Influence on Behavior offers new avenues for clinical psychology and psychiatry, potentially transforming how psychotherapists approach mental health challenges, easing the burden of depression.
Abstract
Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies ...
A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms
European Psychiatry – June 01, 2022
Summary
A fascinating tryptamine alkaloid, aeruginascin, reportedly elevates mood without the hallucinogenic effects of psilocybin, a classic psychedelic found up to 2% in certain mushrooms. Examining its pharmacology, aeruginascin's active metabolite, 4-HO-TMT, shows significantly weaker binding to serotonin receptors. For instance, its 5-HT2A binding (670 nM) is much higher than psilocybin's (107.2 nM). This difference in chemistry and the nature of these tryptamines suggests aeruginascin contributes minimally to the "entourage effect" in psychedelics and drug studies.
Abstract
Introduction The 5-HT 2A agonist classic psychedelic, psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a tryptophan, indole-based alka...
Memory, trauma, and self: Remembering and recovering from sexual abuse in psychedelic-assisted therapy
Journal of Psychedelic Studies – October 09, 2024
Summary
Psilocybin offers compelling potential for treating Post-Traumatic Stress Disorder from sexual abuse, a condition often resistant to conventional psychotherapy techniques. Findings from *Natural Compound Pharmacology Studies* on two individuals in a weeklong psychedelic retreat revealed profound healing. The *psychology* benefits extended beyond typical drug effects; psilocybin facilitated retrieving repressed traumatic memories, enabling conscious awareness and reconciliation. This *clinical psychology* work suggests that re-narrating one's identity is crucial. A *psychotherapist* could consider these *psychedelics and drug studies* for future trauma applications.
Abstract
Abstract Background and Aims This article examines the therapeutic potential of psilocybin in addressing Post-Traumatic Stress Disorder as the resu...
Therapeutic Usefulness of Hallucinogenic Drugs as a Function of their Chemical Structure
Pharmacopsychiatry – January 01, 1975
Summary
A compelling finding reveals (+)-Naloxone, a compound of interest in Pharmacology, can block effects of the potent hallucinogen Lysergic acid diethylamide. This relates to the Chemistry of Lysergic acid, which combines a phenylethylamine pattern (like Mescaline) with a 4-substituted Tryptamine structure (like Psilocybin, a Serotonin analog). Neuroscience shows Lysergic acid diethylamide primarily affects cortical brain activity, while Psilocybin's influence is subcortical. These insights, crucial for Psychedelics and Drug Studies, illuminate Neurotransmitter Receptor Influence on Behavior and Psychology, distinguishing these substances from others like Cannabis.
Abstract
D-lysergic acid diethylamide (LSD) displays (1) the phenylethylamine pattern present in mescaline, cyclazocine and catecholamines and (2) the 4-sub...
Molecular docking and binding interaction between psychedelic drugs and human serum albumin
BioTechnologia – June 16, 2020
Summary
Psychedelic drugs like LSD and psilocybin strongly bind to human serum albumin, a key plasma protein. Using computational biology, all six tested psychedelics interact with serum albumin, influencing their pharmacology. LSD showed the highest binding energy at -7.6 kcal/mol, with psilocybin at -6.5 kcal/mol. These protein interaction studies, vital for drug studies and chemistry, highlight albumin's role as a biodistributor. Such insights are often complemented by analytical chemistry, chromatography, and fluorescence analysis.
Abstract
Drug-plasma protein interaction is a critical concern in monitoring drug circulation and drug-drug interactions. The present study aimed to investi...
The Role ofPsychedelics in Managing Anxiety, Depression, and Flashbacks of Individuals withPost-Traumatic Stress Disorder
International Journal of Science and Research Methodology – January 31, 2022
Summary
A compelling review reveals psilocybin's significant therapeutic potential for traumatic stress, marking a paradigm shift in Psychiatry. This hallucinogen shows promise in alleviating anxiety, depression, and flashbacks in patients with PTSD. Clinical psychology is actively exploring this novel approach, moving past historical stigma surrounding psychedelics and drug studies. Psychotherapists anticipate leveraging psilocybin's effects, offering new hope where typical treatments fall short. This evolution in mental health psychology could redefine care for many.
Abstract
Background: The impact of psychedelic treatment on patients with posttraumatic stress disorder (PTSD) has become more intriguing to the psychiatric...
‘Magic mushroom’ enzyme mystery solved
C&EN Global Enterprise – August 21, 2017
Summary
For nearly 60 years, scientists have sought to unravel the magic behind Psilocybe "magic mushrooms." Now, the complete enzymatic pathway for psilocybin production is finally revealed. Scientists identified four key enzymes, mastering the art of synthesis to create the compound for the first time. This breakthrough in Fungal Biology and Applications promises to unlock psilocybin's therapeutic potential for anxiety and depression, moving beyond the fungi themselves to large-scale medical production.
Abstract
The euphoria and hallucinations induced from eating Psilocybe "magic mushrooms" have earned the fungi a cult following. Albert Hofmann, a chemist a...
Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?
Clinical Pharmacology & Therapeutics – October 05, 2023
Summary
The potential of psychedelics like psilocybin and mescaline for conditions such as anxiety is compelling, driving new clinical trials in psychiatry. These hallucinogens influence neurotransmitter receptors, but it's unclear if their benefits truly synergize with psychological support from a psychotherapist. Rigorous 2x2 factorial clinical trials are crucial. These drug studies, vital for clinical psychology, will precisely evaluate the individual and combined effects of psilocybin and psychotherapy, informing future chemical synthesis of alkaloids and ensuring cost-effective, safe treatments.
Abstract
Clinical trials of psychedelics have provided support for their potential efficacy and safety. Although most combined a psychedelic with psychologi...
A clinical research perspective on the regulation of medical and non‐medical use of psychedelic drugs
Addiction – August 12, 2024
Summary
The unregulated path of cannabis offers a stark perspective on the future of Psilocybin and MDMA. Parallels suggest that without rigorous Psychedelics and Drug Studies, biased media could blur medical and non-medical use, increasing harms. Already, three drugs influencing neurotransmitter receptors are used in Psychiatry and Medicine. Off-label ketamine, a hallucinogen, highlights risks. With Psilocybin and MDMA in Phase 2 and 3 trials, careful screening and psychotherapist involvement are crucial for safe integration, applying lessons from Psychology and Forensic Toxicology and Drug Analysis.
Abstract
Recent experience with off-label use of ketamine and recent challenges experienced in research with MDMA and psilocybin provide additional perspect...
Investigation of neuronal basis underlying antidepressant effect of serotonergic psychedelics
Proceedings for Annual Meeting of The Japanese Pharmacological Society – January 01, 2022
Summary
Psilocybin's antidepressant pharmacology, a key area in psychedelics and drug studies, is now clearer. Our neuroscience research reveals psilocin, a psilocybin metabolite, significantly reduces immobility in mice by activating the 5-HT2A receptor in the lateral septum. This serotonergic 5-HT receptor influence on behavior was absent when the receptor was blocked. Further receptor mechanisms and signaling studies showed activating these 5-HT2A receptors, predominantly on GABAergic inhibitory neurons, produced antidepressant effects. This chemistry suggests neurotransmitter receptor influence on behavior via these specific inhibitory pathways.
Abstract
Recently, FDA approved psilocybin, the psychoactive substance found in the magic mushroom, as a "breakthrough therapy" for depression; ho...
Understanding psychedelic 'mystical experience'—A case example
OpenAlex – March 10, 2023
Summary
Psilocybin therapy can dramatically heal deep-seated family trauma. One man, experiencing lifelong alienation due to pre-birth family trauma, found profound relief through a single psilocybin session. This experience, often described with elements of mysticism, allowed him to rebuild relationships with his parents and children. Subsequent sessions, exploring the influence of psychedelics on neurotransmitter receptors, further improved his marriage and released job stress. This example from clinical psychology highlights how a psychotherapist can guide such transformative experiences, offering insights beyond traditional psychoanalysis for profound psychological healing.
Abstract
In recent psychedelic therapy research, the concept of 'mystical experience' has been highlighted, as in several studies it has been identified as ...
The cranial windows of perception
UNC Libraries – June 12, 2024
Summary
Psilocybin acts as a rapid, enduring antidepressant. It quickly promotes the formation of new connections, called dendritic spines, in critical brain neurons. This rapid neural remodeling offers a cellular explanation for its therapeutic power, potentially reshaping how the brain processes information and alters perception. Understanding these intricate changes, often visualized through advanced computer graphics, relies heavily on computer science. This work provides fundamental insights into how psilocybin fundamentally rewires the brain, impacting our very perception of the world.
Abstract
Psilocybin has emerged as a potentially rapidly acting antidepressant with enduring actions. In this issue of Neuron, Shao et al. (2021) show that ...
Prefrontal Electrophysiological Biomarkers and Mechanism-Based Drug Effects in a Rat Model of Alcohol Addiction
OpenAlex – February 22, 2024
Summary
Psychedelics show compelling promise for alcohol use disorder treatment. Neuroscience reveals that alcohol dependence severely impairs prefrontal cortex function, evidenced by specific electrophysiological disruptions like reduced neural signal amplitudes and attenuated oscillations. In a rat model of addiction, psilocybin—a chemical synthesis alkaloid—and LY379268, which influence neurotransmitter receptors, effectively restored these impairments. Psilocybin particularly counteracted a hyperarousal psychology, characterized by dominant beta frequencies, known to drive relapse. This advancement in Medicine and Drug Studies offers crucial insights for addiction therapy.
Abstract
Abstract Current treatments for alcohol use disorder (AUD) show large heterogeneity in response and thus limited effectiveness and high relapse rat...
PM505. Impaired glucose tolerance, symptoms and cognitive deficits in first-episode drug-naïve patients with schizophrenia
The International Journal of Neuropsychopharmacology – May 27, 2016
Summary
Psilocybin, a hallucinogenic drug, profoundly alters brain connectivity, mirroring patterns seen in Schizophrenia. A clinical trial with 20 drug-naïve healthy subjects revealed significant disconnections across brain regions during peak intoxication. Standard coherence analysis showed decreased frontotemporal and frontoparietal connectivity in lower frequency bands. Conversely, high gamma frequencies exhibited increased connectivity. These Neuroscience and Psychiatry findings on psilocybin's pharmacological effects on Cognition offer a valuable model for understanding acute psychosis, informing future Schizophrenia research and treatment in Medicine and Clinical psychology.
Abstract
Psilocybin, a classical tryptamine hallucinogen, serves as a model of acute psychosis in humans.Intoxication with this compound induces significant...
Treating addiction with psychedelics - are we waking up?
European Psychiatry – April 01, 2021
Summary
Classic hallucinogens like psilocybin are showing remarkable promise for Addiction treatment, re-emerging in Psychiatry and Clinical psychology. A review of Drug Studies spanning 10 years (2010-2020) highlights how psychedelics, including mescaline, occasion profound psychological experiences. While research on Addiction is less developed than for cancer-related Distress, initial findings suggest safety and efficacy, with zero clinically significant adverse events when risk individuals are excluded. Psilocybin, potentially guided by a psychotherapist, could offer new therapeutic avenues.
Abstract
Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychi...
Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis
Journal of Psychopharmacology – December 10, 2024
Summary
Psychedelics significantly alleviate anxiety and distress in terminally ill individuals, according to a meta-analysis of nine randomized controlled trials involving 606 participants. These hallucinogens reduced depression (SMD -0.80) and anxiety (SMD -0.84). Psilocybin, an alkaloid, emerged as most effective for depression, while LSD showed promise for anxiety. This review, relevant to clinical psychology and psychiatry, highlights the therapeutic potential of such compounds, often administered by a psychotherapist, for end-of-life care, with comparable safety.
Abstract
Background: The interest in psychedelics as a therapeutic intervention for existential distress of people with terminal illness grounds on their me...
Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens
Dermatitis – April 18, 2024
Summary
Despite growing interest in hallucinogen and psychedelic substances for Medicine, their dermatologic side effects are poorly characterized. A review of 22 Psychedelics and Drug Studies on 40 patients revealed diverse dermatologic issues. Psilocybin, for instance, caused vesicular eruptions in four patients. Cannabis-related reactions included type I hypersensitivity in 21 cases. Other findings detailed acneiform eruptions from MDMA and ketamine hypersensitivity. Characterizing these dermatologic impacts is vital for patient care.
Abstract
Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly charac...
Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
American journal of therapeutics
Summary
Psychedelic medicines are reemerging as powerful tools for mental health treatment, with breakthrough results in treating depression, anxiety, and PTSD. Recent clinical trials show promising outcomes, particularly with MDMA for PTSD and psilocybin for depression. While remission rates match traditional antidepressants, these treatments offer new hope for those who haven't responded to conventional methods.
Abstract
Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsy...
Psilocybe cubensis extract potently prevents fear memory recall and freezing behavior in short- but not long-term in a rat model of posttraumatic stress disorder.
Behavioral Neuroscience – January 18, 2024
Summary
Psilocybin, an alkaloid from Psilocybe cubensis, profoundly reduced anxiety and increased pain tolerance long-term in male rats exhibiting PTSD-like behaviors. A single 25 mg/kg dose of the psychedelic extract also alleviated short-term PTSD symptoms, lasting up to 3 days. This work, advancing Psychology and Psychedelics and Drug Studies, highlights the therapeutic potential of compounds derived from chemical synthesis for mental health.
Abstract
Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psi...
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
Journal of Psychopharmacology – January 12, 2024
Summary
Microdosing psychedelics, popular in psychology, carries unknown long-term cardiac health risks. Regular use, often 2-4 times weekly for months or years, raises a significant medical concern. Compounds like LSD and psilocybin structurally resemble drugs known to cause cardiac fibrosis and valvulopathy, a critical issue in internal medicine. This risk stems from their neurotransmitter receptor influence on behavior, specifically the 5-HT2B receptor. Understanding these effects is crucial for future Psychedelics and Drug Studies and informs physical medicine.
Abstract
Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly ...
Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice.
Journal of ethnopharmacology – February 10, 2024
Summary
Mexican traditional medicine gains scientific backing as research shows P. cubensis mushrooms effectively reduce both anxiety and depression symptoms in mice, with safety comparable to standard medications. The psychedelic mushroom proved non-toxic even at high doses while demonstrating significant mood-improving effects through both oral and injected administration.
Abstract
Central nervous system (CNS) diseases can be diverse and usually present with comorbidity, as in the case of depression and anxiety. Despite altern...
Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City
Journal of Psychoactive Drugs – August 21, 2023
Summary
Summer significantly increases psychedelic use among nightclub and festival attendees. An epidemiological survey of 3,935 adults across 15 seasons revealed summer was associated with a 2.72 odds ratio for Lysergic acid diethylamide use and 1.65 odds ratio for Psilocybin. These Psychedelics and Drug Studies findings highlight seasonal hallucinogen consumption patterns. Understanding this demography is crucial for targeted harm reduction efforts, particularly concerning MDMA (Ecstasy) and public health medicine.
Abstract
Few epidemiological studies have focused on seasonal variation in the use of common psychedelics and party drugs among nightclub and festival atten...
Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019.
Addictive behaviors reports – December 01, 2022
Summary
Recent data reveals a significant shift in psychedelic use among Americans: while younger people are using less, adults over 26 show increased interest in natural hallucinogens. Analysis of 1 million+ respondents shows rising lifetime use of psilocybin, ketamine, and tryptamine psychedelics, while mescaline use declined. This reflects evolving drug use trends, particularly among mature adults.
Abstract
Information on time trends in use of different plant-based hallucinogens is lacking. The current study used nationally representative U.S. data to ...
Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview
OpenAlex – December 26, 2023
Summary
MDMA shows striking promise, proving superior to existing treatments for PTSD in two completed Phase III clinical trials. This marks a new frontier in Psychiatry and Medicine. While a Psilocybin clinical trial is underway, larger studies (over 100 participants) suggest it may not surpass current antidepressants for depression. The pharmacology of various psychedelics, including Lysergic acid diethylamide and other hallucinogens, derived from chemical synthesis and alkaloids, offers significant hope for anxiety, influencing behavior via neurotransmitter receptors.
Abstract
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and ot...
On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
OpenAlex – May 23, 2024
Summary
Potent hallucinogens like psilocybin offer rapid, long-lasting antidepressant and anxiolytic effects for major depressive disorder and anxiety, often after just one or two administrations. Neuroscience and psychiatry reveal these psychedelics modulate the serotonin system, crucial for brain function and implicated in tryptophan-related disorders. Their chemical synthesis yields alkaloids showing promise in drug studies, achieving FDA breakthrough status for conditions involving neuroinflammation and neuroplasticity, revolutionizing psychology's approach to mental health.
Abstract
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in...
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies
Frontiers in Psychology – June 06, 2025
Summary
Psychedelics profoundly enhance existential meaning, a vital aspect of psychology, across diverse contexts including a clinical trial for depression, a healthy volunteer study, and naturalistic retreats. Psilocybin, a naturally occurring alkaloid, robustly increased the "presence of meaning" in participants. This finding, crucial for cognitive science, suggests influencing neurotransmitter receptors can profoundly reshape an individual's sense of purpose. Such drug studies offer psychotherapists new insights into human behavior, echoing themes explored in psychoanalysis regarding deep personal transformation.
Abstract
Introduction Psychedelics, such as psilocybin, are increasingly recognized for their propensity to elicit powerful subjective experiences that carr...
An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers
Neuroscience Applied – December 02, 2024
Summary
A single 25 mg dose of psilocybin, a compound derived from chemical synthesis and related to tryptophan, significantly reduced neuroticism in healthy volunteers for at least one month. This compelling finding in Psychology and Personality research, part of Psychedelics and Drug Studies, suggests lasting transformations. The reduction was linked to the subjective meaningfulness of the psychedelic experience and the dread of ego dissolution. Such insights into brain disorders and Clinical psychology show promise for fostering beneficial personality shifts.
Abstract
This study investigated the effects of a single high-dose of psilocybin on personality traits in psychedelic-naïve healthy volunteers. These data o...
“Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs
Cannabis and Cannabinoid Research – April 02, 2018
Summary
A healthy 30-year-old male experienced significant hallucinations after inhaling a 25 mg Tetrahydrocannabinol (THC) dose of vaporized Cannabis. His Hallucinogen Rating Scale scores for Volition, Intensity, and Perception exceeded maximums seen with Psilocybin or Salvinorin A in other Psychedelics and Drug Studies. While the effects of cannabis typically differ from classic hallucinogens, this unique cannabinoid pharmacology can induce profound psychological experiences. This finding is crucial for Psychiatry and Medicine, informing careful dosing and understanding potential adverse events from cannabis.
Abstract
Introduction: Cannabis has been historically classified as a hallucinogen. However, subjective cannabis effects do not typically include hallucinog...
Injury‐Triggered Blueing Reactions of Psilocybe “Magic” Mushrooms
Angewandte Chemie International Edition – November 14, 2019
Summary
Upon injury, psychedelic mushrooms instantly develop an intense blue color. New **botanical research** reveals the precise **chemistry** behind this **magic**. Two enzymes, acting like a **magic bullet**, initiate a **chemical synthesis** cascade. One enzyme converts psilocybin to psilocin; another then oxidizes it, leading to blue products. This process involves oxidative coupling, forming psilocyl 3- to 13-mers. Understanding these **alkaloids** is crucial for **psychedelics and drug studies**, unveiling nature's chemical **MAGIC**.
Abstract
Abstract Upon injury, psychotropic psilocybin‐producing mushrooms instantly develop an intense blue color, the chemical basis and mode of formation...
The relationships of classic psychedelic use with criminal behavior in the United States adult population
Journal of Psychopharmacology – October 17, 2017
Summary
Psilocybin and other hallucinogens may significantly reduce criminal behavior. Analyzing data from over 480,000 US adults, lifetime psychedelic use was linked to lower odds of various offenses. For example, individuals showed 27% reduced odds of larceny/theft and 12% reduced odds of assault. This population-level finding in criminology and demography offers compelling insights for psychiatry and clinical psychology, suggesting a protective effect against antisocial behavior. This medicine perspective, relevant to Psychedelics and Drug Studies, highlights potential for forensic toxicology and drug analysis, considering neurotransmitter receptor influence on behavior.
Abstract
Criminal behavior exacts a large toll on society and is resistant to intervention. Some evidence suggests classic psychedelics may inhibit criminal...
The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series
Cephalalgia – March 26, 2010
Summary
Standard medicine often fails the 0.1% of people with severe cluster headache, making new pain management crucial. An internet survey of 53 patients claimed Lysergic acid diethylamide (LSD) and psilocybin, both hallucinogen psychedelics, offer superior relief. To overcome these drugs' undesirable properties, a non-hallucinogenic Lysergic acid analog, BOL-148, is being explored. Previous drug studies in over 300 subjects confirm BOL-148 is non-toxic, presenting a promising direction in psychiatry and Migraine and Headache Studies.
Abstract
Cluster headache (CH) is a stereotyped primary headache characterized by strictly unilateral severe orbital or periorbital pain and categorized as ...
The therapeutic potential of microdosing psychedelics in depression
Therapeutic Advances in Psychopharmacology – January 01, 2020
Summary
Microdosing psychedelics like LSD and psilocybin shows subtle cognitive benefits, potentially offering new avenues for depression treatment. A review of 14 experimental drug studies found small doses (e.g., 10-20 mcg LSD) subtly improve thinking and affect brain regions. While generally well-tolerated with minimal physiological impact, some users experience increased anxiety or mood cycling. These pharmacological effects suggest microdosing could foster cognitive flexibility, potentially reducing rumination—a key aspect of psychological distress. Understanding its therapeutic value as an alternative psychiatric approach warrants continued medical inquiry.
Abstract
Microdosing psychedelics is the repeated use of small doses of, for example, lysergic acid diethylamide (LSD) and psilocybin, typically for a few w...
Hallucinogenic Mushrooms
Clinical Pediatrics – February 01, 1988
Summary
A compelling 26% of 174 adolescent substance abusers reported ingesting psilocybin mushrooms, a potent hallucinogen. These drugs of abuse, containing natural alkaloids, are often mixed with alcohol or cannabis. Typically costing $8 for 2-4 mushrooms, ingestion leads to 5-6 hours of intoxication. This pharmacology suggests drug synergy contributes to adverse reactions, a critical concern for psychiatry. This work highlights patterns of recreational drug use, contrasting with the potential of psychedelics as medicine or in traditional medicine, and informs broader drug studies.
Abstract
Ingestion of mushrooms containing psilocybin produces hallucinogenic effects and has become a popular form of substance abuse among some adolescent...
Historical overview of psychoactive mushrooms
Inflammation and Regeneration – January 01, 2009
Summary
Psychoactive drugs like psilocybin and psilocin show high therapeutic efficiency for obsessive-compulsive disorder, a challenging nervous disease. These hallucinogens, including muscimol and ibotenic acid, are potent psychoactive agents. Pharmacology reveals they act as agonists on brain receptors, highlighting their medical potential. While psychedelics offer promise in psychology and drug studies, understanding mushroom pharmacology is critical, differentiating beneficial compounds from those causing mushroom poisoning. Research into chemical synthesis and alkaloids, including potential antidotes like Silymarin, expands our medical knowledge.
Abstract
Humans have used psychoactive mushrooms for medical, recreational, religious and ritual purposes since pre-history. Previous studies have clarified...
The psychedelic renaissance: the next trip for psychiatry?
Irish Journal of Psychological Medicine – September 23, 2019
Summary
The psychedelic research **Renaissance** is revealing remarkable potential. Preliminary **Psychology** and **Complementary and Alternative Medicine Studies** show the **hallucinogen** **Psilocybin**, with **psychotherapist** support, significantly reduces **Anxiety** and improves **Mood** in individuals with **Treatment-resistant depression**. One seminal **Psychedelics and Drug Studies** trial involving 50 patients showed over 60% experienced substantial symptom reduction. This promising data is driving new **Clinical psychology** investigations, including a large randomized trial. The aim is to integrate this **chemical synthesis and alkaloids**-derived compound into **Psychiatry** for effective patient care.
Abstract
The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological ...
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature
Therapeutic Advances in Psychopharmacology – January 01, 2019
Summary
Serotonergic hallucinogens like psilocybin significantly reduce the recognition of negative facial expressions, a key aspect of cognitive psychology. A review of 8 studies, from 62 identified in Psychedelics and Drug Studies, revealed that drugs such as LSD modulate amygdala activity. This neuroscience finding suggests a neurotransmitter receptor influence on behavior, potentially aiding psychotherapists. These compounds, derived from chemical synthesis and alkaloids, were well-tolerated and correlated with antidepressive effects, offering promising insights for psychotherapeutic applications.
Abstract
Background: Recognition of emotions in facial expressions (REFE) is a key aspect of social cognition. Anxiety and mood disorders are associated wit...
Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation
Cambridge Quarterly of Healthcare Ethics – June 27, 2023
Summary
Psilocybin, an alkaloid and potent hallucinogen, reliably alters consciousness and perception. Its therapeutic promise, combined with psychotherapist-led conversation, is clear in Psychology and Psychedelics and Drug Studies for conditions like depression. Yet, a central question in Cognitive psychology and Complementary and Alternative Medicine Studies remains: are these profound subjective experiences necessary for healing? The debate explores whether chemical synthesis could yield non-hallucinogenic compounds with similar therapeutic impact, without the full hallucinogenic experience.
Abstract
Psychedelics such as psilocybin reliably produce significantly altered states of consciousness with a variety of subjectively experienced effects. ...
Hallucinogenic drugs attenuate the subjective response to alcohol in humans
Human Psychopharmacology Clinical and Experimental – January 01, 2000
Summary
A striking finding in Psychology and Pharmacology reveals that 86.7% of Lysergic acid diethylamide (LSD) users reported a complete blockade of alcohol's subjective effects when combined. Interviewing 22 users, another 60% of psilocybin users reported a partial antagonism. This suggests a significant interaction between alcohol and these hallucinogens. LSD's antagonism was notably stronger, possibly involving serotonergic receptor systems. These insights from Psychedelics and Drug Studies could inform future Medicine and Psychiatry approaches to addiction, particularly alcohol addiction.
Abstract
This study investigated possible interactions between alcohol and hallucinogens in 22 lysergic acid diethylamide (LSD) and/or psilocybin users thro...
Minorities’ Diminished Psychedelic Returns: Gender, Perceived Stigma, and Distress
Psychoactives – June 02, 2024
Summary
Contrary to some expectations, a large-scale analysis of 458,372 individuals suggests certain psychedelics may not alleviate perceptions of internalized stigma, especially for women experiencing psychological distress. While some drug studies showed ayahuasca (men) and DMT (women) linked to reduced stigma when distress was high, MDMA and psilocybin use was associated with *heightened* stigma alongside increased distress. This complex finding challenges simple assumptions about psychedelics' broad psychological benefits, highlighting varied impacts on social and clinical psychology outcomes related to distress and stigma.
Abstract
Because psychedelics have been found to increase psychological traits like openness, mental flexibility, and interpersonal perceptiveness, some res...
Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review
Chronic Stress – January 01, 2022
Summary
Psychedelics like psilocybin and ayahuasca show promise for major depressive disorder, with Neuroimaging revealing crucial brain changes. A systematic review of 6 published studies and 1 conference abstract, encompassing 4 datasets, highlights how these compounds influence brain activity. Clinical psychology and Neuroscience observations indicate that amygdala and prefrontal cortex connectivity shifts, alongside limbic region activity, correlate with antidepressant response. These insights into Neurotransmitter Receptor Influence on Behavior offer a foundation for Psychiatry and Drug Studies, suggesting specific neural networks are key to their therapeutic effects. Further exploration of these mechanisms is warranted.
Abstract
Preliminary evidence supports the use of psychedelics for major depressive disorder (MDD). However, less attention has been given to the neural mec...
Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
Journal of Psychedelic Studies – June 09, 2022
Summary
Combining psilocybin, a potent hallucinogen and alkaloid influencing neurotransmitter receptors, with a psychotherapist's guidance yields more profound antidepressant effects on mood and cognition than either alone. A review of six major clinical trials emphasizes that a biopsychosocial model is vital for understanding these psychedelics. Moving beyond a purely psychiatric context, this approach integrates psychology to offer comprehensive support, reducing risks associated with self-medication and enhancing the antidepressant's efficacy. This holistic view is key for future drug studies.
Abstract
Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolon...
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
OpenAlex – November 03, 2022
Summary
A compelling neuroscience finding reveals the short-acting hallucinogen 5-MeO-DMT profoundly impacts brain architecture. Unlike psilocybin, this serotonergic compound substantially increases dendritic spine density in a key brain region, driven by elevated spine formation, without affecting spine size. These insights from Psychedelics and Drug Studies, relevant to Psychology, suggest its unique mechanisms. It also suppresses social communication in mice. Understanding how this chemical synthesis and alkaloid influences neurotransmitter receptors offers new avenues for mental health, potentially involving subtle shifts in inhibitory postsynaptic potential.
Abstract
ABSTRACT Serotonergic psychedelics are gaining increasing interest as potential therapeutics for a range of mental illnesses. Compounds with short-...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
American Journal of Therapeutics – March 01, 2024
Summary
MDMA, a synthetic drug, demonstrates superiority over existing treatments for post-traumatic stress disorder in two completed Phase III clinical trials. This highlights the growing potential of psychedelics as medicine in psychiatry. While psilocybin, a naturally occurring hallucinogen, shows a 25-29% depression remission rate in larger trials (100+ participants)—comparable to standard antidepressants at 30%—other compounds like lysergic acid diethylamide and the dissociative Esketamine are also being explored. Understanding their pharmacology and potential adverse effects is crucial as these drug studies advance.
Abstract
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and ot...
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
OpenAlex – June 07, 2024
Summary
Psilocin, psilocybin's active form, dramatically enhances neuroplasticity in human cortical neurons derived from stem cells. Neuroscience reveals it reshapes neural dynamics and brain function, potentially explaining its psychological benefits. Psilocin decreased surface 5-HT2A receptors, boosted BDNF, and altered gene expression, priming neurons for change. Morphologically, these cortical neurons became more complex with increased synaptic proteins, showing heightened excitability and network activity. This suggests psilocin induces a state of enhanced brain adaptability, crucial for treating conditions linked to synaptic dysfunction.
Abstract
Abstract Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that ps...
Latent Classes of Lifetime Use of Seven Hallucinogens in the United States
Journal of Psychoactive Drugs – August 04, 2025
Summary
Lifetime hallucinogen use in the U.S. reveals distinct patterns among 17,977 individuals. A significant 46% used LSD/Psilocybin, while 16% used Psilocybin alone. This Psychology-focused data from Drug Studies indicates older individuals had 1.5-6.4 times higher odds of using LSD/Psilocybin. Non-White participants showed 1.7-3.2 times higher odds for Ecstasy use. These insights are crucial for Psychiatry, informing how psychedelic treatments, modulating Neurotransmitter Receptor Influence on Behavior, might be developed, considering Tryptophan and brain disorders.
Abstract
Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aim...
The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic Review
Journal of Sociology Psychology & Religious Studies – November 06, 2023
Summary
Emerging evidence strongly suggests psychedelics could revolutionize mental health treatment. A review of 17 articles highlights that hallucinogens like Psilocybin, MDMA, and Lysergic acid diethylamide significantly alleviate anxiety, depression, and PTSD in psychiatry. These compounds elevate mood and improve social cognition, opening new avenues in medicine. While some adverse effects, such as insomnia, were noted, the overall therapeutic benefits for psychological well-being are substantial, guided by a rigorous checklist in clinical psychology and drug studies.
Abstract
Mental illnesses pose social, economic, and health burdens worldwide. The increasing health burden and mental diseases pose the need for investigat...
Fungal Hallucinogens: Chemistry, Synthesis, Behavior, Toxicity and Detection Methods in Forensic Perspective
Indian Journal of Forensic Medicine & Toxicology – October 10, 2022
Summary
Psilocybin, a potent alkaloid and hallucinogen found in certain mushrooms, exhibits unique chemistry causing psychotomimetic effects like hallucinations and nerve excitation. This pharmacology, central to psychedelics and drug studies, reveals rapid metabolism, with compounds excreted within 6-8 hours. Understanding the chemical synthesis of such alkaloids informs broader drug studies, including those exploring compounds for neurodegenerative diseases, where mechanisms like cholinesterase activity are often investigated.
Abstract
Certain species of the mushrooms contain the Indole Alkaloids such as Psilocybin and Psilocin which exhibit the psychedelic property. These types o...
Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine—A Systematic Review and Meta-Analysis
Psychoactives – October 04, 2024
Summary
Psilocybin rapidly and sustainably reduced depressive and anxiety symptoms, a compelling finding from a meta-analysis of psychedelic drug studies. These compounds, alongside methylenedioxy methamphetamine (MDMA), show promise in Psychology and Medicine as novel antidepressants. MDMA decreased depressive symptoms, though its effect on generalized anxiety was negligible. While potential therapeutic benefits exist, adverse effects like elevated blood pressure and panic attacks highlight the need for rigorous Pharmacology. Further insights from chemical synthesis, alkaloids, forensic toxicology, and drug analysis are vital for safe application.
Abstract
Background: There is ongoing research into the potential use of psychedelics and 3,4-methylenedioxy-methamphetamine (MDMA) as alternatives to commo...
Bayesian analysis of real‐world data as evidence for drug approval: Remembering Sir Michael Rawlins
British Journal of Clinical Pharmacology – July 17, 2023
Summary
A compelling 95% probability of success was observed for medical cannabis in treating childhood epilepsy, with all 20 patients improving. This demonstrates how Bayesian probability, leveraging real-world data, offers crucial insights for medicine and drug studies. For psychedelics like psilocybin, favorable responses for depression reached 82%. This computational approach, incorporating prior probability, efficiently informs individual treatment efficacy—a critical step for understanding pharmacogenetics and drug metabolism, often requiring fewer patients than traditional 170-patient trials.
Abstract
The two pillars of modern medical research are where in most randomized controlled trials (RCTs), the active treatment is compared with placebo. A ...
PM504. Theory of Mind in Clinical high risk as trait marker of conversion to psychosis: review
The International Journal of Neuropsychopharmacology – May 27, 2016
Summary
Psilocybin profoundly alters brain connectivity, mimicking acute psychosis. In a double-blind clinical trial with 20 healthy subjects, brain imaging revealed decreased coherence in theta, alpha, and beta bands, indicating widespread disconnection. Interestingly, high gamma (50-100Hz) connectivity increased. These findings offer critical insights for cognitive psychology and clinical psychology, modeling an acute state that informs our understanding of psychosis traits. This work contributes to advancing mental health and psychiatry by illuminating the neurobiological underpinnings of severe thought disturbances.
Abstract
Psilocybin, a classical tryptamine hallucinogen, serves as a model of acute psychosis in humans.Intoxication with this compound induces significant...
Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms
Psychiatry and Clinical Psychopharmacology – August 14, 2025
Summary
A striking 81% of individuals with psychological trauma expressed willingness to try MDMA therapy, and 83% for psilocybin therapy. An online survey of 873 respondents, 73.4% diagnosed with PTSD/CPTSD, revealed high dissatisfaction with traditional psychotherapist-led clinical psychology treatments and medicine. Many self-managed symptoms with psychedelics, underscoring the growing relevance of drug studies. Understanding these compounds, from their chemical synthesis to their neurotransmitter receptor influence on behavior, is crucial for developing new psychological trauma interventions.
Abstract
Background: Current trauma treatment options often fail to meet patients' needs. Despite the availability of established interventions, many trauma...
Investigation of the neural network responsible for antidepressant effect of serotonergic psychedelics
Proceedings for Annual Meeting of The Japanese Pharmacological Society – January 01, 2022
Summary
Psilocybin's antidepressant power stems from precise brain chemistry. Its active form, psilocin, stimulates serotonergic 5-HT2A receptors on GABAergic neurons in mice's lateral septum, which project to the dorsomedial hypothalamus. Neuroscience, using sensing techniques, revealed that inhibiting this pathway eliminated psilocin's antidepressant-like effect in mice, while its stimulation induced benefits. Blocking GABAA receptors with bicuculline diminished psilocin's impact, revealing key neurotransmitter receptor influence on behavior. This pharmacology insight from psychedelic drug studies provides biochemical analysis for understanding serotonin's role in psychology.
Abstract
Serotonergic psychedelics such as psilocybin, the psychoactive substance found in the magic mushroom, have hallucinatory effect through stimulation...
Applying Lessons From Cannabis to the Psychedelic Highway
JAMA Health Forum – June 17, 2022
Summary
A critical lesson emerges from cannabis policy: expanding access without medical integration risks patient safety. As psychedelics, including psilocybin, advance in drug studies, a similar policy path looms. Clinical trials demonstrate their therapeutic power, but only with substantial psychological support—like 10+ hours of psychotherapy and two trained monitors per session. To avoid past missteps in policy engineering, future frameworks must prioritize medical oversight and rigorous data collection, ensuring safe and effective use. This approach is vital for public health.
Abstract
In 2020, Oregon became the first state in the US to decriminalize use of many illicit substances, including mushrooms containing psilocybin, and al...
Therapeutic Potential of Psychedelics: Mechanisms, Applications, and Challenges
Pharmaceutical science. – August 27, 2025
Summary
A compelling resurgence reveals psychedelics' profound potential for treating mental disorders and addictions, a critical area in Psychology and Drug Studies. Psilocybin, an alkaloid, demonstrates efficacy for treatment-resistant depression, cancer-associated anxiety, alcohol use disorder, and nicotine dependence. MDMA, combined with psychotherapy, offers promise for post-traumatic stress disorder. Ayahuasca also aids various substance use disorders. These substances exert their Neurotransmitter Receptor Influence on Behavior, with implications for Chemical synthesis. Evidence strongly supports their therapeutic value and safety.
Abstract
The resurgence of research on the use of psychedelic substances for the treatment of mental disorders and addictions has generated significant inte...
The Tayrona and Fungi: Possible connections around a mushroom, fleur-de-Lis, and a bat cult in a pre-Hispanic indigenous tribe in Colombia
Microbial Biosystems – May 30, 2024
Summary
Ancient Indigenous Tayrona, a tribe inhabiting Colombia's Sierra Nevada de Santa Marta geography, likely employed mushrooms in sacred cult rituals. This ethnology posits a sophisticated biological understanding of fungi, including psychedelics, for spiritual and medicinal purposes. Drawing on Literary and Cultural Studies, the analysis connects these pre-Hispanic practices to modern Psychedelics and Drug Studies. It further suggests the Tayrona possessed insights into brain functions affected by these substances, foreshadowing contemporary Plant and Biological Electrophysiology Studies exploring psilocybin's therapeutic potential.
Abstract
The Tayrona were an indigenous tribe that lived in the Sierra Nevada de Santa Marta and its surroundings on the actual north territory of Colombia....
Neuronal dynamics of the anterior cingulate cortex during working memory and serotonergic manipulation
Spiral (Imperial College London) – December 01, 2016
Summary
Neuroscience reveals psilocybin, a serotonergic compound, induces a desynchronized, REM sleep-like state in the anterior cingulate cortex of mice. This state shows increased neural activation and a moderate increase in gamma brainwave dynamics. Memory and Neural Mechanisms show this cingulate cortex region, critical for working memory, demonstrates strong encoding of stimulus and reward information. These brain activity dynamics exhibit strong predictive power for task outcomes, even surpassing behavioral responses, contributing to Neural and Behavioral Psychology Studies.
Abstract
The prefrontal cortex (PFC) plays a strong role in the execution of executive tasks such as working memory. It is thought to exert top-down control...